From Chairman Bob Proulx’s Address to Shareholders at the 2018 Annual General Meeting, held 31 May, 2018:
“We all know that far to many people’s lives are adversely affected by cancer and so our mission is clear — we have to develop a new, more sensitive way to detect and diagnose cancer.”
Read Chairman’s Address to Shareholders — 2017 Annual General Meeting
MELBOURNE – Imagion Biosystems (ASX:IBX), a company dedicated to improving healthcare through the early detection of cancer, today announced the appointment of Mr Brett Mitchell
Download a copy of the AGM 2024 presentation deck HERE. AGM 2024 Video Transcript: Good morning, ladies and gentlemen. My name is Robert Crew and
Highlights: Announced positive results from IBI10103 Phase I Study demonstrating safety and clinical feasibility of molecular MRI with MagSense® HER2 Imaging Agent Presented new animal
We’re on a mission to make cancer more detectable.
Imagion Biosystems (IBX) is an innovative medical imaging company that uses bio-safe magnetic nanoparticles to detect cancer and other diseases.
Stay informed about our latest news and developments.
© Imagion Biosystems, Ltd. All Rights Reserved | Privacy Policy | Terms & Conditions | Careers | Corporate Governance